ROLE OF CONTRACEPTION IN IMPROVING WOMEN´S QUALITY OF LIFE ASSOCIATED WITH PMS AND OTHER MENSTRUAL DISORDERS

Abstract

Objective – to assess the quality of life (QOL) of women with premenstrual syndrome (PMS) from moderate to severe degree in combination with other symptoms of the menstrual cycle with use of the combined oral contraceptive containing 20 mcg of ethinyl estradiol (EE) and 3 mg of drospirenone (DRSP) under scheme 24/4.Material and methods. A single-center, prospective, cohort, non-randomized, uncontrolled study was conducted. On the basis of screening of 360 women 27 patients with PMS of moderate and severe forms were selected. The control group consisted of 18 women without PMS. Diagnosis of PMS was based on standardized ICD-10 criteria, the psychological state was assessed by the hospital anxiety and depression scale HADS, QOL index – by the short form of the SF-36 questionnaire. The evaluation was carried out twice – before beginning treatment and in 3 months after the treatment.Results. Assessment of QOL showed that as compared with the baseline parameters they significantly improved in 3 months of treatment by scales that assess PP (physical pain: 56.0 ± 28.9 vs 76.2 ± 18.9, p = 0.020), RE (role of emotional problems in limitation of life activity: 57.8 ± 21.3 vs 77.9 ± 18.3, p = 0.040), SA (social activity: 42.5 ± 13,5 vs 72,5 ± 12,8, p = 0.050) and MH (mental health: 62,0 ± 7,3 vs 72.0 ± 6.3, p = 0.048). 88.4% of the subjects expressed high satisfaction with the treatment results.Conclusion. Symptoms of PMS and other disorders of the menstrual cycle successfully stopped for 3 months by a combination of 20EE/DRSP, which is accompanied by a reduction in the incidence of anxiety and depression and improving in QOL.

Keywords

• premenstrual syndrome
• quality of life
• anxiety
• depression
• coc
• drospirenone
• leia